Citriodiol® and Impetigo
Ключови думи
Резюме
Описание
The extract of lemon eucalyptus, a common plant, has since the 1970s been used in commercial insect repellent products. Recently, it has been shown that lemon eucalyptus has potent anti-bacterial and anti-fungal effects that should assist in the treatment of inflammatory conditions such as impetigo. Our aim is to investigate this further by investigating the safety and efficacy of this product in the treatment of Impetigo.
A randomised, double-blinded, three-armed pilot study, involving a total of 30 patients will be recruited from the dermatology outpatient department clinic at Royal North Shore hospital for this study. These patients will be between the ages of 12 months and 12 years with a clinical diagnosis of Impetigo.
The three treatment groups will include a 2% or 5% topical p-menthane-3,8-diol (extracted from lemon eucalyptus) and a topical Mupirocin arm, which will be applied topically twice a day till resolution of symptoms. Follow-up will occur weekly until resolution of symptoms, which is expected within 2 weeks. Photographs, disease severity assessment and lesional swabs for culture will be taken at recruitment and as progress.
Дати
| Последна проверка: | 05/31/2012 |
| Първо изпратено: | 05/28/2012 |
| Очаквано записване подадено: | 05/30/2012 |
| Първо публикувано: | 06/04/2012 |
| Изпратена последна актуализация: | 06/17/2012 |
| Последна актуализация публикувана: | 06/19/2012 |
| Действителна начална дата на проучването: | 06/30/2012 |
| Приблизителна дата на първично завършване: | 12/31/2012 |
| Очаквана дата на завършване на проучването: | 02/28/2013 |
Състояние или заболяване
Интервенция / лечение
Drug: p-menthane-3,8-diol oil
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Experimental: 2% PMDO | |
| Experimental: 5% PMDO | |
| Active Comparator: Mupirocin |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 12 Months Да се 12 Months |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: - age between 12 months and 12 years - dermatologist-confirmed impetigo - written informed consent provided by parents Exclusion Criteria: - impetigo requiring oral/systemic therapy - diagnosis of another form of staphylococcal or streptococcal disease (eg, cellulitis, erysipelas, abscess) - serious local infection (eg, cellulitis, abscess, wound infection) or systemic infection - oral or topical antibiotics - known allergy to topical insect repellents - patients receiving systemic corticosteroids, immunosuppressive agents, radiation therapy, chemotherapy within 1 month prior to entry into study - history of any clinically significant or poorly controlled cardiac, haematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, psychiatric, and/or other major disease as determined by the investigator - current enrollment in any other trial of an investigational drug within 30 days prior to study drug administration - other unspecified reasons, in the opinion of the investigator that makes the patient unsuitable for enrollment. |
Резултат
Първични изходни мерки
1. Improvement in severity score of impetigo [2 weeks]
